Effects of Hypoxia or Caffeine on 4km Time-trial Morning Cycling.
This study aims to implement a rigorously standardized protocol to investigate the effect of acute (60 min prior) caffeine intake or hypoxia (1000m and 2000m) on 4km time trial performance.
Обзор исследования
Статус
Статус
Условия
Условия
Вмешательство/лечение
Вмешательство/лечение
Подробное описание
Time-trial performance is widely regarded as the gold-standard measure of endurance exercise capacity, because successful performance depends on completing a fixed distance in the shortest possible time while effectively regulating pacing strategy and power output. As a result, time-trial performance is considered as one of the most ecologically valid measures of endurance performance in both laboratory investigations and applied sport settings. For many endurance athletes, training and competition frequently occur during the morning due to event scheduling, travel requirements and environmental considerations. However, the morning period is characterised by several time-of-day-related physiological differences that may negatively influence exercise performance. Although systematic reviews have reported substantial variability in the magnitude of diurnal fluctuations in time-trial performance, evidence from well-controlled laboratory studies using fixed-distance protocols under thermoneutral conditions consistently indicates superior performance during the late afternoon or evening. Specifically, improvements in evening performance have been observed across a range of endurance modalities, including 100-m swimming (2.6%), 1-km cycling (2.3%), 4-km cycling (2.6%), 10-km cycling (2.3%), 10-km treadmill running (6.3%), and 16.1-km cycling (3.6%). These findings suggest that morning time-trial performance may be compromised relative to later times-of-day, potentially due to circadian variations in physiological and psychological readiness for exercise. Given that athletes are often required to compete in the morning despite these potential limitations, identifying practical and effective strategies to enhance morning time-trial performance is of considerable interest to athletes, coaches and practitioners seeking to optimise competitive outcomes.
Among the nutritional strategies proposed to improve morning performance, acute caffeine ingestion remains one of the most widely consumed and extensively studied ergogenic aids. Caffeine (1,3,7-trimethylxanthine) primarily exerts its performance-enhancing effects through antagonism of adenosine receptors in the central nervous system, resulting in increased arousal, reduced perceptions of fatigue, and enhanced neurotransmitter activity, including dopamine and noradrenaline. These neurophysiological effects collectively promote wakefulness, attention and central motor drive, thereby facilitating exercise performance. Consistent with these mechanisms, substantial evidence demonstrates that caffeine can improve endurance exercise capacity and time-trial performance across a variety of exercise modalities. Despite the well-established ergogenic effects of caffeine, research examining its efficacy during morning time-trial exercise remains comparatively limited. Interpretation of the available literature is further complicated by several methodological shortcomings, including inconsistent caffeine dosing protocols, inadequate familiarisation procedures and poor control of habitual caffeine intake. Recognising the importance of habitual caffeine consumption as a moderator of physiological and performance responses, recent classification thresholds have been proposed. Categorising individuals as naïve (<25 mg·day-¹), low (25 mg·day-¹ to 0.99 mg·kg-¹·day-¹), mild (1.00-2.99 mg·kg-¹·day-¹), moderate (3.00-5.99 mg·kg-¹·day-¹), high (6.00-8.99 mg·kg-¹·day-¹), and very high (>9.00 mg·kg-¹·day-¹) caffeine consumers. Failure to adequately characterise and control habitual caffeine intake may therefore contribute to the variability observed across studies.
Additional methodological limitations within the existing literature include the absence of both placebo and no-pill comparator conditions, together with insufficient control of key chronobiological variables such as chronotype, sleep quality, habitual training time, and seasonal influences. These factors are particularly relevant given their established influence on exercise performance and their potential to confound assessments of both circadian variation and caffeine-related ergogenic effects. Indeed, recent systematic reviews have identified substantial methodological heterogeneity and risk of bias across chronobiology studies, highlighting the need for more rigorous and standardised experimental designs when investigating time-of-day effects on exercise performance. Consequently, well-controlled studies are required to determine whether acute caffeine ingestion can meaningfully attenuate the physiological disadvantages associated with morning endurance exercise and improve time-trial performance under ecologically valid conditions.
Therefore, the primary aim of the present study was to determine whether the ergogenic effects of acute caffeine (CAFF) ingestion, administered 60-min before exercise, enhance morning 4-km cycling time-trial performance when evaluated when behavioural, methodological and chronobiological confounders were carefully controlled. Habitual caffeine consumers with an intake of >150 mg·day-¹ were recruited to minimise the potential influence of caffeine tolerance and withdrawal, while maximising the physiological response to the administered 300 mg caffeine dose. Secondary outcomes included measures of core and skin temperature, ratings of perceived exertion (RPE), mood-state and physiological responses to exercise.
Тип исследования
Тип исследования
Регистрация (Оцененный)
Регистрация
Фаза
Фаза
- Фаза 4
Контакты и местонахождение
Контакты исследования
Контакты исследования
- Имя: Ben J Edwards, PhD
- Номер телефона: 01519046238
- Электронная почта: B.J.Edwards@ljmu.ac.uk
Места учебы
-
-
Merseyside
-
Liverpool, Merseyside, Соединенное Королевство, L3 3AF
- Рекрутинг
- Tom Reilly Building
-
Контакт:
- Joao Agulhari, BSc
- Номер телефона: 07379664724
- Электронная почта: jpagulhari@gmail.com
-
-
Критерии участия
Критерии приемлемости
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Age: 18-30 years old
- Healthy (as determined by the pre-participation questionnaire)
- >2 years aerobically trained individuals
- Consume >150 mg/day of caffeine
- Be able to stick to the retiring and waking schedule of the study as well as no exercise 24 h before and no caffeine.
Exclusion Criteria:
- Age: <18 or >30 years old
- Consume <150 mg/day of caffeine hence caffeine naïve
- Those with a history of significant side effects after the consumption of caffeine.
- Deemed unhealthy/unable to perform exercise determined by PAR-Q
- Shift worker or having travelled out of the UK time zone within the last month of testing
- Muscle related injury or broken/fractured bone within the past 3 years Diagnosed sleep disorder
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Другой
- Распределение: Рандомизированный
- Интервенционная модель: Назначение кроссовера
- Маскировка: Двойной
Количество рук
Оружие и интервенции
Группа участников / АрмияГруппа участников / Армия |
Вмешательство/лечениеВмешательство/лечение |
|---|---|
|
Экспериментальный: ABCDE
Control, Placebo, Caffeine, 1000m, 2000m, |
300 mg of caffeine ingested in form of 3 100 mg capsules 60 minutes prior to testing.
Другие имена:
Placebo capsules made to resemble caffeine. 3 pills the same size as caffeine but filled with maltodextrin (~1.6 g)
Другие имена:
No pill control intended to act as a comparator for both Hypoxia and caffeine analysis
Другие имена:
Hypoxia intervention ran in a controlled environmental chamber on site. Set oxygen partial concentration to similar levels at 1000 m altitude.
Другие имена:
Hypoxia intervention ran in a controlled environmental chamber on site. Set oxygen partial concentration to similar levels at 2000 m altitude.
Другие имена:
|
|
Экспериментальный: BCDEA
Placebo, Caffeine, 1000m, 2000m, Control, |
300 mg of caffeine ingested in form of 3 100 mg capsules 60 minutes prior to testing.
Другие имена:
Placebo capsules made to resemble caffeine. 3 pills the same size as caffeine but filled with maltodextrin (~1.6 g)
Другие имена:
No pill control intended to act as a comparator for both Hypoxia and caffeine analysis
Другие имена:
Hypoxia intervention ran in a controlled environmental chamber on site. Set oxygen partial concentration to similar levels at 1000 m altitude.
Другие имена:
Hypoxia intervention ran in a controlled environmental chamber on site. Set oxygen partial concentration to similar levels at 2000 m altitude.
Другие имена:
|
|
Экспериментальный: CDEAB
Caffeine, 1000m, 2000m, Control, Placebo, |
300 mg of caffeine ingested in form of 3 100 mg capsules 60 minutes prior to testing.
Другие имена:
Placebo capsules made to resemble caffeine. 3 pills the same size as caffeine but filled with maltodextrin (~1.6 g)
Другие имена:
No pill control intended to act as a comparator for both Hypoxia and caffeine analysis
Другие имена:
Hypoxia intervention ran in a controlled environmental chamber on site. Set oxygen partial concentration to similar levels at 1000 m altitude.
Другие имена:
Hypoxia intervention ran in a controlled environmental chamber on site. Set oxygen partial concentration to similar levels at 2000 m altitude.
Другие имена:
|
|
Экспериментальный: DEABC
2000m, Control, Placebo, Caffeine, 1000m, |
300 mg of caffeine ingested in form of 3 100 mg capsules 60 minutes prior to testing.
Другие имена:
Placebo capsules made to resemble caffeine. 3 pills the same size as caffeine but filled with maltodextrin (~1.6 g)
Другие имена:
No pill control intended to act as a comparator for both Hypoxia and caffeine analysis
Другие имена:
Hypoxia intervention ran in a controlled environmental chamber on site. Set oxygen partial concentration to similar levels at 1000 m altitude.
Другие имена:
Hypoxia intervention ran in a controlled environmental chamber on site. Set oxygen partial concentration to similar levels at 2000 m altitude.
Другие имена:
|
|
Экспериментальный: EABCD
1000m, 2000m, Control, Placebo, Caffeine, Caffeine, |
300 mg of caffeine ingested in form of 3 100 mg capsules 60 minutes prior to testing.
Другие имена:
Placebo capsules made to resemble caffeine. 3 pills the same size as caffeine but filled with maltodextrin (~1.6 g)
Другие имена:
No pill control intended to act as a comparator for both Hypoxia and caffeine analysis
Другие имена:
Hypoxia intervention ran in a controlled environmental chamber on site. Set oxygen partial concentration to similar levels at 1000 m altitude.
Другие имена:
Hypoxia intervention ran in a controlled environmental chamber on site. Set oxygen partial concentration to similar levels at 2000 m altitude.
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
4km time to completion
Временное ограничение: 5 weeks
|
How long does the participant take to complete 4km cycling |
5 weeks
|
|
Average power
Временное ограничение: 5 weekas
|
Average power sustained through the 4km |
5 weekas
|
Вторичные показатели результатов
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Cognitive function
Временное ограничение: 5 weeks
|
Stroop word-colour interference test |
5 weeks
|
|
Witty
Временное ограничение: 5 weeks
|
Light reaction test |
5 weeks
|
|
Memory test
Временное ограничение: 5 weeks
|
Rey's Auditory Verbal Learning test |
5 weeks
|
Соавторы и исследователи
Спонсор
Спонсор
Даты записи исследования
Изучение основных дат
Начало исследования (Оцененный)
Начало исследования
Первичное завершение (Оцененный)
Первичное завершение
Завершение исследования (Оцененный)
Завершение исследования
Даты регистрации исследования
Первый отправленный
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Первый опубликованный
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее опубликованное обновление
Последнее отправленное обновление, отвечающее критериям контроля качества
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Признаки и симптомы, Респираторные
- Патологические состояния, признаки и симптомы
- Признаки и симптомы
- Гипоксия
- Средние соединения
- Органические химические вещества
- Гетероциклические соединения
- Гетероциклические соединения, 2-кольцо
- Гетероциклические соединения, слитое кольцо
- Карбоновые кислоты
- Алкалоиды
- Анилиды
- Амиды
- Анилиновые соединения
- Амины
- Ацетанилиды
- Пуриноны
- Пурины
- Кислоты, карбоциклический
- бета-лактамы
- Лактамы
- Цефалоспорины
- Тиазины
- Фенилпропионаты
- Ксантины
- Ацетаминофен
- Кофеин
- Ибупрофен
- Цефалексин
- 2-(3',4'-dihydroxyphenyl)ethylene sulfate
- 5'-palmitoyl cytarabine
- temoporfin-polyethylene glycol conjugate
Другие идентификационные номера исследования
Другие идентификационные номера исследования
- 261020LJMUSPSREC348
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .